Newly diagnosed AML in older adults: Results for venetoclax
Thursday, November 29, 2018 - 10:40
in Health & Medicine
Clinical trial results show a 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts.